A Phase 2 Open-label (Core Phase Plus Extension Phase) With 2 Cohorts Study to Assess the Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Than 6 Years Old

Principal Investigator

Prof Laurent Servais

Contact us

Email: childrensresearch@ouh.nhs.uk

IRAS number

1010236